Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-06-16T20:40:51.579Z Has data issue: false hasContentIssue false

P02-196 - Case Report: Behaviour Alteration with Brain Iron Accumulation

Published online by Cambridge University Press:  17 April 2020

M. Lazaro
Affiliation:
Nuestra Señora de Sonsoles hospital, Avila, Spain
N. Echeverria
Affiliation:
Nuestra Señora de Sonsoles hospital, Avila, Spain
J.R. Rodriguez
Affiliation:
Nuestra Señora de Sonsoles hospital, Avila, Spain
F. De La Torre
Affiliation:
Nuestra Señora de Sonsoles hospital, Avila, Spain
S. Escribano
Affiliation:
Nuestra Señora de Sonsoles hospital, Avila, Spain
J.I. Bango
Affiliation:
Nuestra Señora de Sonsoles hospital, Avila, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

To analyze psychiatric symptoms in relation to a case of Hallervorden-Spatz disease (neurodegeneration with brain iron accumulation (NBIA) or pantothenate kinase-associated neurodegeneration - familial brain degeneration with iron deposition in brain).

Methods

Pubmed revision on behaviour alteration and its relation to brain iron accumulation. Review of patient medical records, including image studies.

Results

A 52-year-old female with diagnosis of mental retardation and psychosis was treated and followed since 1999. Severe behaviour alteration motivated hospital admission in 2009. Over the last two years, the patient had developed progressive dementia, choreoathetosis, mutism, ideomotor apraxia, urinary and fecal incontinence, and corticospinal signs.

A brain MRI (2008) revealed iron deposits in basal ganglia, hypointensity with an area of central hyperintensity (“eye-of-the-tiger”-sign) in both globus pallidi on T2. Based on clinical and MRI findings a diagnosis of Hallervorden Spatz Disease was made.

Classic form of the disease is characterized by early onset and rapid progression, culminating in early death. Atypical disease, as in our case report, has a later onset and more slowly progressive course.

Systemic chelating agents have not proved beneficial. Treatment remains symptomatic. Our patient has experienced a favourable response to low-dose trazodone and quetiapine.

Conclusions

At times, behavioral changes may predate neurologic manifestations, whereas at other times disturbances in mental status and physical functioning may coexist. Among patients with NBIA, those with atypical disease are much more likely to have psychiatric symptoms with cognitive decline. These features present in our case report usually make a difficult and late diagnosis and treatment.

Type
Others
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.